Biopharma Insights

ReproCell, IBM, and HNCDI Debut Pharmacology-AI to Boost Efficiency of Drug Discovery

ReproCell, a well-established life sciences company, recently revealed its latest service offering, Pharmacology-AI. This service is the result of a completed EXCELERATE project, coordinated by the Hartree National Centre for …

Continue ›››

Seqera Labs Joins Forces with Genomics England to Boost Genomic Medicine Research

Seqera Labs, recognized for its secure workflow orchestration software in the life sciences domain, is aligning forces with Genomics England, a government-owned entity, which initiated the notable 100,000 Genomes Project …

Continue ›››

FDA IND Approval of AI-derived Cancer Drug ISM3091 Marks a Milestone for Insilico Medicine

In an essential leap forward for the utilization of artificial intelligence (AI) in drug discovery, Insilico Medicine secured Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration …

Continue ›››

Eli Lilly Collaborates with XtalPi to Harness AI in Drug Discovery

XtalPi Inc., a company that uses artificial intelligence (AI) and automation in pharmaceutical technology, is set to collaborate with Eli Lilly and Company on a project in the AI drug …

Continue ›››

Neuralink's Journey and the Broadening Horizons of Brain-Computer Interface Technology

Neuralink, Elon Musk's brain-implant company, has just revealed that it received approval from the U.S. Food and Drug Administration (FDA) for its inaugural human clinical trial. This development, disclosed on …

Continue ›››

Valo Therapeutics' Innovative Immuno-Oncology Therapy PeptiCRAd-1 Begins Human Trials

Valo Therapeutics Oy (ValoTx), a frontrunner in the development of advanced immunotherapies for cancer, has initiated its Phase I trial of PeptiCRAd-1, a pioneer in the realm of immuno-oncology. The …

Continue ›››

How Syntekabio’s Supercomputing Enables AI-driven Drug Discovery

FDA Recognizes SiSaf's siRNA Therapy, SIS-101-ADO, for Autosomal Dominant Osteopetrosis Treatment

In a noteworthy development in the pharmaceutical industry, SiSaf Ltd, a renowned RNA delivery and therapeutics firm, recently announced that the U.S. FDA has granted Orphan Drug Designation and Rare …

Continue ›››

LabGenius Showcases AI-Driven Antibody Discovery Platform in a T-cell Engager Demonstration

London-based LabGenius, known for its innovative approach to antibody discovery, recently revealed impressive results from its research platform demonstration project. This project showcased the company's machine learning-driven lead optimization capacity, …

Continue ›››

ReproCell, IBM, and HNCDI Debut Pharmacology-AI to Boost Efficiency of Drug Discovery

Seqera Labs Joins Forces with Genomics England to Boost Genomic Medicine Research

FDA IND Approval of AI-derived Cancer Drug ISM3091 Marks a Milestone for Insilico Medicine

Eli Lilly Collaborates with XtalPi to Harness AI in Drug Discovery

Neuralink's Journey and the Broadening Horizons of Brain-Computer Interface Technology

Valo Therapeutics' Innovative Immuno-Oncology Therapy PeptiCRAd-1 Begins Human Trials

How Syntekabio’s Supercomputing Enables AI-driven Drug Discovery

FDA Recognizes SiSaf's siRNA Therapy, SIS-101-ADO, for Autosomal Dominant Osteopetrosis Treatment

LabGenius Showcases AI-Driven Antibody Discovery Platform in a T-cell Engager Demonstration

Bruker Acquires ZONTAL, Boosting Digital Transformation in Pharma Laboratories

Advancing Cell-free Biocomputing

From Qubits to Cures: The Promise of Quantum Computing in Pharmaceutical Research and Development (a Realistic View)